Kymera Therapeutics

Yahoo Finance • 25 days ago

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report d... Full story

Yahoo Finance • last month

Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?

Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now. The company currently commands an optimistic outlook, with management remaining confident in achieving key clinical endpoints and biomarker data. This... Full story

Yahoo Finance • last month

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today a... Full story

Yahoo Finance • 2 months ago

Wednesday's ETF with Unusual Volume: FYC

The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the... Full story

Yahoo Finance • 2 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story

Yahoo Finance • 2 months ago

Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline

Introduction & Market Context Kymera Therapeutics (NASDAQ:KYMR) presented its second quarter 2025 financial results on August 11, 2025, highlighting progress across its immunology pipeline despite a significant revenue decline. The compan... Full story

Yahoo Finance • 2 months ago

Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market

Kymera Therapeutics Inc (NASDAQ:KYMR [https://www.chartmill.com/stock/quote/KYMR]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company’s stock saw a pre... Full story

Yahoo Finance • 2 months ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD)... Full story

Yahoo Finance • 3 months ago

Gilead sees Q2 EPS hit from IPR&D expenses

[Gilead corporate headquarters in Silicon Valley] Sundry Photography * Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process re... Full story

Yahoo Finance • 3 months ago

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow

There’s no doubt about it: the stock market’s strong performance over the past few months is fueling an optimistic mood. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics stock price target lowered to $65 at Brookline Capital

Investing.com - Brookline Capital Markets has lowered its price target on Kymera Therapeutics (NASDAQ:KYMR) to $65.00 from $70.00 while maintaining a Buy rating on the stock. The new target represents a significant upside from the current... Full story

Yahoo Finance • 3 months ago

Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating

Investing.com - Morgan Stanley initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Overweight rating and a $70.00 price target, highlighting the company’s protein degradation and drug discovery expertise. The stock has shown st... Full story

Yahoo Finance • 3 months ago

Tuesday's Insider Activity: Major Buys and Sells Shake Up Markets

This article summarizes the top insider buys and sells reported on Tuesday, July 1, 2025, for US stocks. Top Insider Buys: Kymera Therapeutics Inc (NASDAQ:KYMR): A group of directors, including Mark N Lampert, collectively purchased $13... Full story

Yahoo Finance • 3 months ago

Monday's Insider Activity: Top Buys and Sells in US Stocks

This article summarizes the most significant insider buys and sells reported for US stocks on Monday, June 30, 2025. Top Insider Buys: • Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw substantial insider buying from Baker Bros. Advisors and... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics: Baker Bros acquire $28.8m in shares

Baker Bros. Advisors and related entities reported purchasing shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 30, 2025. The biotechnology company, currently valued at $2.89 billion, has shown strong momentum with a 41% return ove... Full story

Yahoo Finance • 4 months ago

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KY... Full story

Yahoo Finance • 4 months ago

Kymera price target raised to $54 from $51 at BofA on pipeline updates

Investing.com - BofA Securities raised its price target on Kymera Therapeutics (NASDAQ:KYMR) to $54.00 from $51.00 on Thursday, while maintaining a Buy rating on the stock following several pipeline developments. The stock, currently tradi... Full story

Yahoo Finance • 4 months ago

Kymera’s partnerships with Sanofi and Gilead drive value

Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. The firm reiterated its Outperform rating while lowering... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics prices $250M stock offering

* Kymera Therapeutics (NASDAQ:KYMR [https://seekingalpha.com/symbol/KYMR]) priced [https://seekingalpha.com/pr/20150243-kymera-therapeutics-announces-pricing-of-250-million-public-offering] its underwritten public offering of $250.8M sha... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story